ALB and focal segmental glomerulosclerosis: To determine the optimal therapeutic dose of the YSHS granule for the alleviation of renal injury in the ADR-induced FSGS mouse model, the doses of 2,000, 4,000 and 8,000 mg/kg body weight of the YSHS granule were administered by gavage once daily, and the urinary albumin/creatinine ratio (UACR), which is one of the most sensitive and reliable response indicators of early renal injury (Basset et al., 2022), was measured after 4 weeks of intragastric administration of the YSHS granule.